Mounjaro could minimise asthma symptoms, new study suggests

Ed Milner | Last update: 31st July 2025

TL;DR

• GLP-1 weight loss drugs may help control asthma symptoms in people with obesity

• New study shows users had fewer flare-ups and better lung function

• Researchers suggest these jabs could become part of asthma management

• The drugs are already being studied for heart health, cancer, and dementia benefits

• SlimrChat says: the health perks just keep stacking up

Can Mounjaro really help with asthma?

A new peer-reviewed study published in Advances in Therapy has found that people with obesity and asthma who were prescribed GLP-1 drugs like Mounjaro (tirzepatide) and Wegovy (semaglutide) experienced fewer asthma attacks and reported improved overall symptom control.

The research, led by teams from the University of Aberdeen and the University of East Anglia, followed over 400 patients across the UK and found a significant drop in asthma-related complications once they began weight loss treatment.

You can read the full study from Advances in Therapy here.

Another unexpected benefit?

This adds to the growing list of surprising health perks linked to weight loss jabs. Previously, Mounjaro has been linked to a reduced risk of dementia and even lower cancer rates in some groups.

🔗 Read: Mounjaro and dementia — new study finds risk may drop
🔗 Also read: Can Mounjaro help fight cancer?

As researchers note, carrying excess weight can worsen inflammation and put pressure on the lungs — both of which are known triggers for asthma symptoms. By promoting weight loss and reducing systemic inflammation, GLP-1 drugs may help ease the burden on the respiratory system.

What this means for SlimrChat users

If you’re living with asthma and obesity, this could be another reason to speak to your doctor or healthcare provider about weight loss treatment options.

While these findings are early, they’re promising — and highlight that the benefits of weight loss jabs go far beyond the number on the scale.